<h2 class="mt-4 text-lg font-medium text-color-lightgreytext" data-astro-cid-fjd3bvuv>
Summary from the AllSides News Team
</h2> <div class="mt-2 text-md editor-content" data-astro-cid-fjd3bvuv><p>Pfizer-BioNTech has begun a study comparing its original COVID-19 vaccine with doses specially altered&nbsp;to combat the Omicron variant.</p>

<p>The study will involve&nbsp;three trials in adults ages 18-55 to determine if a vaccine specifically for the Omicron variant is more effective than the shots that are currently given.</p>

<p>It is not clear that a change in the vaccine will be ordered, since areas where the Omicron surge began are already seeing a <a href="/story/omicron-covid-19-surge-starting-peak">decrease in cases</a>, and since future variants may not resemble Omicron.&nbsp; In&nbsp;the meantime, the original vaccine still offers good protection against severe illness and death.</p>
</div> <h2 class="mb-2 leading-6 text-lg text-gray-500 font-medium mt-4 p-0">
Featured Coverage of this Story
</h2> <div class="flex gap-5 my-2 mb-8 md:flex-row flex-col"> <div class="flex-1 left"><div class="mb-2 font-bold border-solid global-bias-label text-color-left border-b-[3px] text-s border-color-left">From the Left</div><a id="News-Item--pfizer-opens-study-of-covid-shots-updated-to-match-omicron" href="https://apnews.com/article/pfizer-covid-vaccine-omicron-study-63cc1e6ee7c9c23e8795ce9bbd448ce9" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">Pfizer opens study of COVID shots updated to match omicron</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">Associated Press</p></div><img src="https://img.allsides.com/sites/default/files/bias-left.png" alt="AllSides Media Bias Rating: Left" title="AllSides Media Bias Rating: Left" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/1000_243.jpeg" alt="Pfizer opens study of COVID shots updated to match omicron" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">AP Photo/Charles Krupa</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the hugely contagious&nbsp;omicron variant.</p><p>Pfizer and its partner BioNTech announced the study on Tuesday.</p><p>COVID-19 vaccine-makers have been updating their shots to better match omicron in case global health authorities decide the change is needed.</p><p>Omicron is more likely than previous variants to cause infection even in people who’ve been vaccinated, but it’s not yet clear that a change to the vaccine recipe will be ordered. Among the issues regulators are weighing: Some of...</div><a id="Open-On--associated-press" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://apnews.com/article/pfizer-covid-vaccine-omicron-study-63cc1e6ee7c9c23e8795ce9bbd448ce9" target="_blank" rel="noopener">
Open on Associated Press<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a></div></div><script type="968073ac565091855f9efa62-module" src="/_astro/story-related-news.astro_astro_type_script_index_0_lang.DjPUAy8u.js"></script><div class="flex-1 left"><div class="mb-2 font-bold border-solid global-bias-label text-color-left border-b-[3px] text-s border-color-left">From the Left</div><a id="News-Item--pfizer-and-biontech-announce-plans-to-test-omicron-specific-covid-19-vaccine-in-adult-trials" href="https://www.usatoday.com/story/news/health/2022/01/25/covid-pfizer-biontech-test-omicron-vaccine/9204215002/" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">Pfizer and BioNTech announce plans to test omicron-specific COVID-19 vaccine in adult trials</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">USA TODAY</p></div><img src="https://img.allsides.com/sites/default/files/bias-leaning-left.png" alt="AllSides Media Bias Rating: Lean Left" title="AllSides Media Bias Rating: Lean Left" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/2d059ea7-b91b-4f86-a65e-eac090936537-AP_Virus_Outbreak_US.jpeg" alt="Pfizer and BioNTech announce plans to test omicron-specific COVID-19 vaccine in adult trials" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">LM Otero, AP Images</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>Vaccine makers Pfizer and BioNTech announced plans early Tuesday to test an omicron-specific COVID-19 vaccine in people.&nbsp;</p><p>The companies will run three simultaneous trials in adults ages 18-55 to determine if an omicron-specific vaccine is more effective than current shots.</p><p>The existing vaccine was developed to target the original or "ancestral" strain of COVID-19. While three shots appear&nbsp;to provide some protection against omicron, the vaccine, called Comirnaty, is not as effective as it was against earlier strains.</p><p>“This study is part of our science-based approach to develop a variant-based vaccine...</div><a id="Open-On--usa-today" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://www.usatoday.com/story/news/health/2022/01/25/covid-pfizer-biontech-test-omicron-vaccine/9204215002/" target="_blank" rel="noopener">
Open on USA TODAY<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a><div class="flex-1 whitespace-nowrap text-gray-500 text-xs leading-4 flex mt-2"><div class="hover:cursor-help" data-tippy-content="<p><span style=&#34;white-space: nowrap;&#34;>Some content from this outlet may be</span><br><span style=&#34;white-space: nowrap;&#34;>limited or behind a paywall.</span></p>"><i class="fa-regular fa-sack-dollar mr-1"></i><span class="whitespace-nowrap">Possible Paywall</span></div></div></div></div><div class="flex-1 right"><div class="mb-2 font-bold border-solid global-bias-label text-color-right border-b-[3px] text-s border-color-right">From the Right</div><a id="News-Item--pfizer-biontech-begin-omicron-specific-covid-19-vaccine-study" href="https://www.foxbusiness.com/lifestyle/omicron-specific-covid-vaccine-study-pfizer-biontech" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">Fox Business</p></div><img src="https://img.allsides.com/sites/default/files/bias-leaning-right.png" alt="AllSides Media Bias Rating: Lean Right" title="AllSides Media Bias Rating: Lean Right" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/needle-xxxx.jpg" alt="Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">Fox Business</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>COVID-19&nbsp;vaccine-makers&nbsp;Pfizer and BioNTech announced Tuesday that they would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.&nbsp;</p><p>The companies said there would be three trials examining different regimens of the current Pfizer-BioNTech vaccine for an omicron-based vaccine.</p><p>The study will also draw upon&nbsp;some participants from the companies’&nbsp;Phase 3&nbsp;COVID-19 booster study, evaluating up to 1,420 people.&nbsp;</p><p>The first cohort received two doses of the Pfizer-BioNTech vaccine 90-180 days before enrollment and will receive one or two doses of the omicron-based vaccine.&nbsp;</p><p>In the second, participants received three doses...</div><a id="Open-On--fox-business" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://www.foxbusiness.com/lifestyle/omicron-specific-covid-vaccine-study-pfizer-biontech" target="_blank" rel="noopener">
Open on Fox Business<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a></div></div> </div> <p class="mt-2 mb-5 text-right"> <a id="More-headline-roundups" class="group relative pr-5 hover:no-underline border-b border-opacity-0 hover:border-opacity-100 border-color-text inline-block w-fit cursor-pointer text-sm no-underline" href="/headline-roundups">